Intuitive Surgical, Inc. develops, manufactures, and markets surgical systems and related products, and its financial statements provide information on assets, liabilities, stockholders' equity, revenue, expenses, and comprehensive income for the three and six months ended June 30, 2021. The financial statements also detail cash flows, operating activities, investing activities, and financing activities, along with significant accounting policies, risks, uncertainties, and recent accounting pronouncements affecting the company. As of June 30, 2021, the company's total transaction price allocated to remaining performance obligations was $1,700 million, with contract assets at $43.4 million, and deferred revenue at $392.0 million. Revenue recognition involves contract assets and liabilities, lease arrangements, and revenue from sales and operating leases, with recognition of revenue over time for service contracts and lease arrangements. The company also includes information on intuitive system leasing revenue, lease maturities for sales-type leases, and details on goodwill, intangible assets, as well as potential legal challenges related to product liability and patent litigation. Overall, the company's financial position is stable and profitable, but it faces risks and uncertainties associated with the COVID-19 pandemic.
Intuitive Surgical, Inc. provides a detailed overview of its financial performance and operations, with a focus on the period ending June 30, 2021. The company relies on forward-looking statements to discuss the anticipated effects of the COVID-19 pandemic on its business, financial state, and operational outcomes. Its report highlights the da Vinci Surgical Systems and related products, emphasizing how the pandemic has impacted procedure volumes and system demand in different regions. Despite facing challenges, the company notes varying recovery rates influenced by factors like vaccination distributions and government interventions. Additionally, the pandemic has increased worldwide economic uncertainties, affecting the company's current operations and future plans. Moreover, the text outlines the regulatory clearances and technological advancements achieved by the medical technology company, including approvals for surgical systems and devices in countries like the EU, Japan, and South Korea. As part of its strategic focus, the company emphasizes new product launches and the utilization of robotic-assisted surgeries across various medical specialties. The impact of the COVID-19 pandemic on procedure volumes and system placements is discussed, along with factors shaping future demand for the da Vinci Surgical Systems. These factors encompass economic conditions, geopolitical influences, regulatory endorsements, competitive landscape, and market dynamics.
There have been no significant changes in the market risk for the company during the first half of 2021 compared to the disclosures made in their previous annual report for 2020.
The text discusses the evaluation of disclosure controls and procedures maintained by a company to ensure timely and accurate reporting of information required by the SEC. The company's management, including the principal executive and financial officers, conducted an evaluation and concluded that the disclosure controls and procedures were effective at a reasonable assurance level. Additionally, it is mentioned that there have been no significant changes in the company's internal control over financial reporting during the most recent fiscal quarter.
The text provided is an excerpt regarding legal proceedings, directing readers to refer to specific financial information included in the company's quarterly report for further details.
The text discusses the various risks related to the business operations of a company. It focuses on issues such as reliance on sole and single-source suppliers affecting product demand, disruptions in the supply chain for materials like semiconductors, and potential price increases leading to difficulties in meeting product demand. Additionally, it highlights the risks associated with information technology systems interruptions, cyber attacks, and breaches in data security, which could harm business operations, customer relations, financial condition, and reputation. The company relies on external vendors for certain aspects of its information technology systems, and defects or vulnerabilities in their systems could compromise the security of the company's own data. Despite efforts to protect systems and data, security breaches could lead to significant costs, service interruptions, and potential damage to the company's reputation and financial standing.
The text discusses the issuer's activity related to the sales and repurchases of equity securities. It highlights that there were no unregistered sales of equity securities during the reported period. Moreover, it presents a table summarizing the issuer's stock repurchase activity for the quarter ended June 30, 2021, indicating the total number of shares repurchased and the remaining funds available under the stock repurchase program. The issuer authorized up to $7.5 billion for stock repurchases, with $1.6 billion remaining available for share repurchases as of June 30, 2021. The authorized stock repurchase program does not have an expiration date.
The text provided states that there have been no defaults on senior securities.
The text provided states that there are no mine safety disclosures applicable to the context being discussed.
The text provided is a list of items with only one item listed, which states that there is no other information to report.
The provided text includes details about various exhibits related to Intuitive Surgical, Inc., such as its amended certificates of incorporation, bylaws, incentive award plan, and certifications under the Sarbanes-Oxley Act of 2002. It also mentions the Inline XBRL-formatted financial statements and cover page from the company's quarterly report for June 30, 2021. Additionally, it includes a signature confirming the report's authenticity and is signed by Marshall L. Mohr, Executive Vice President and Chief Financial Officer of Intuitive Surgical, Inc., on July 21, 2021.
